Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yuhan Corp.

eng.yuhan.co.kr/Main/

Latest From Yuhan Corp.

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies

Eisai Joins PROTAC Club Through New Oncology Collab

Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.

Cancer Platform Technologies

Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.

South Korea Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Gastrointestinal
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Yuhan Corp.
  • Senior Management
  • Jung Hee Lee, Pres. & CEO
  • Contact Info
  • Yuhan Corp.
    Phone: 2 828 0181
    74, Noryangjin-Ro
    Dongjak-Gu
    Seoul,
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register